WO2000000639A2 - Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin - Google Patents
Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin Download PDFInfo
- Publication number
- WO2000000639A2 WO2000000639A2 PCT/EP1999/004501 EP9904501W WO0000639A2 WO 2000000639 A2 WO2000000639 A2 WO 2000000639A2 EP 9904501 W EP9904501 W EP 9904501W WO 0000639 A2 WO0000639 A2 WO 0000639A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leptin
- response element
- compound
- stat
- cell line
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Definitions
- the invention relates to a novel method and more particularly to a method for the detection of compounds that mimic, potentiate or inhibit the physiological effects of the 5 leptin. These methods can also be used to measure the functional activity of preparations of leptin and leptin mimetics, potentiators or inhibitors.
- Obesity is the result of an imbalance in energy intake and expenditure. Increasingly prevalent, this condition is associated with a number of pathological conditions including non-insulin dependent diabetes (NIDDM) 1 , cardiovascular disease, and NIDDM 1 .
- leptin 15 tissue hormone leptin, a recently discovered factor that acts on the hypothalamus to inhibit food intake and increase energy expenditure (1).
- leptin a recently discovered factor that acts on the hypothalamus to inhibit food intake and increase energy expenditure (1).
- the importance of leptin in the regulation of energy balance is accentuated by the profound early onset obesity, hyperinsulinaemia and insulin resistance exhibited by obese (ob/ob) mice, the genetic strain that lacks a functional leptin (1).
- mice 20 these mice, and to a lesser extent their lean littermates, exhibit a marked loss in weight and a lowering of plasma insulin and glucose concentrations (2,3).
- a phenotypically similar strain, the diabetic (db/db) mouse has a defect in the leptin receptor and has been shown to be unresponsive to leptin in a number of in vivo and in vitro experiments (4-8).
- examples of leptin deficiency in humans demonstrate that the
- Protein molecules that contain a core composed of four ⁇ -helices forming a bundle of up-up-down-down topology comprise a family of cytokines and growth factors. Proteins of this family cause homo- and hetero-oligomerisation of membrane receptors
- Receptors of the family which are activated by oligomerisation fall into two broad classes; those such as epidermal growth factor receptor, which possess integral tyrosine kinase activity in their intracellular domains (11), and those such as the IL4 and erythropoietin receptors, which lack this activity and mediate their response by way of an associated protein tyrosine
- Both receptor subtypes are activated by cytokines, but the 4-helix bundle proteins activate only the non-integral tyrosine kinase subtype.
- the non-integral protein tyrosine kinase receptors generally act, at least in part, through a pathway involving Janus kinase (JAK) and their associated signal transducers and activators of transcription (STAT) proteins. On activation STAT proteins bind to DNA response elements thereby
- Oligonucleotide sequences comprising DNA regulatory elements of the general sequence TT(N)nAA have been identified (13) as STAT response elements. These elements bind STAT proteins in response to signalling molecules such as cvtokines.
- the leptin receptor (OB-R) (14) is related to class I cytokine receptors which include gpl30, the common signal transducing component for IL-6 related cytokines that are known to activate latent cytosolic STAT proteins (15).
- Multiple OB-R isoforms exist, of which at least two, OB-Ra and OB-Rb, are generated by alternative splicing
- the short isoforms, OB-Ra, OB-Rc and OB-Rd contain 34, 32 and 40 amino acid cytosolic C-terminals, respectively.
- the OB-Rb isoform contains a full-length cytosolic domain of 302 amino acids which includes binding motifs required for activation of the Janus Kinase/Signal Transduction and Activator of Transcription (JAK/STAT) signalling pathway.
- a point mutation (G- T) in the mouse diabetes (db) gene results in a novel splice donor site and a premature translation termination (4,5).
- OB-R(db) lacks the sequence motifs required for the interaction with JAK and STAT and evidence from the db/db mouse model suggests that OB-Rb is the sole receptor that can mediate JAK/STAT activation and leptin-mediated effects on food intake and cell proliferation (4,5,16).
- leptin is characterised by a four helix bundle tertiary structure.
- leptin interacts with membrane-bound receptors, one of which(QB-Rb),activates a JAK-STAT kinase cascade (17).
- This interaction forms the basis for an assay system for the detection of compounds that mimic, potentiate or inhibit the physiological effects of leptin.
- Such an assay has utility in selecting compounds for the treatment of weight, energy balance, haematopoietic, fertility and other disorders modulated by leptin.
- the assay is especially useful for selecting compounds for the treatment of those disorders related to obesity, anorexia, cachexia and diabetes.
- leptin rapidly induced nuclear STAT5 DNA binding activity in +/+ and ob/ob jejunum, but had no effect in the OB-Rb deficient db/db mouse.
- Leptin administration results in a 2-fold reduction in apolipoprotein AIV (APO-AIV) transcript levels, 90 minutes after fat load.
- APO-AIV apolipoprotein AIV
- leptin can mediate, through a OB-Rb and a STAT5 mechanism, a negative-feedback signal to the primary site of lipid handling. Lack of leptin or resistance to direct leptin action in this site may contribute to elevated triglyceride and lipoprotein levels observed in obesity and its related syndromes.
- the invention provides a method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of leptin, which method comprises:
- a suitable polypeptide which is capable of mediating the stimulation by leptin of a leptin activated STAT DNA response element is a functional isoform of the ob-gene receptor, for example that identified in Tartaglia et al, Cell, 1995, 83, 1263.
- a suitable polypeptide which is capable of enhancing the stimulation by leptin of an activated STAT is a functional isoform of the ob-gene receptor, for example that identified in Tartaglia et al, Cell, 1995, 83, 1263.
- DNA response element is a JAK kinase, especially JAK-2, or a STAT, especially STAT 3 or 5.
- the response element is coupled to a promoter gene, preferably a minimal promoter.
- a suitable response element is a nucleotide of formula TT(N) n AA, where N is any nucleotide and n is 4, 5 or 6.
- a favoured response element is selectively activated by the intracellular events mediated by leptin interacting with its receptor.
- Such selective response elements can be determined by examining the relative activation of a range of response element-reporter gene constructs when transfected into an ob-responsive cell line by leptin versus other cytokines.
- a favoured response element is a nucleotide of formula TT(N) n AA, where N is any nucleotide and n is 4 or 5.
- a further suitable response element is TTCCCGGAA.
- a further suitable response element is that region of the promoter of a gene regulated by the leptin that is required for STAT interactions. This gene will depend on the particular therapeutic use of the compounds to be selected by the assay.
- a suitable reporter gene is firefly luciferase or chloramphenicol acetyltransferase enzyme.
- a suitable promoter is a minimal promoter such as the herpes simplex virus thymidine kinase or SV40 promoter.
- Figure 1 Expression of the leptin receptor (OB-R) mRNA isoforms in tissues from the gastrointestinal tract and in human CACO-2 cells.
- O-R leptin receptor
- RT-PCR detection as described in experimental procedures, of the multiple OB-R isoforms in discrete regions of the tract in lean (+/+) and obese (ob/ob) mice; OB- Re (1), OB-Rd (2), OB-Rc (3), OB-Rb (4), OB-Ra (5) and finally a lOObp DNA ladder.
- leptin specific primers were used to rule out contamination from fat and detection of illegitimate transcription.
- a positive control a common sequence from the extracellular domain of OB-R was amplified from the same samples.
- the right panel shows RT-PCR detection of the functional leptin receptor OB-Rb in the human CACO-2 cell line.
- Figure 2 Western blot analysis of the OB-R receptor in the gastrointestinal tract and CACO-2 cells.
- A. OB-Ra detected in different sections of the tract of both +/+ and ob/ob mice using a antibody raised against the carboxy terminal of the short isoform.
- OB-R detected in the human CACO-2 cells using antibody raised against the amino terminus that is common to all OB-R isoforms. Arrows point at an approximate size of a
- Figure 3 Relative expression levels of the total OB-R transcript in different sections of the gastrointestinal tract.
- Top panel shows representative gels of PCR amplification of the common OB-R extracellular domain in various sections of the gastrointestinal tract of the +/+ mouse, using different amounts of cDNA as described previously (18). The amount of cDNA in each sample was related to ⁇ -actin levels and adjusted before dilutions were performed.
- Lower panel shows the quantitation of OB-R mRNA normalised to the ⁇ -actin mRNA, from the optimised linear regions of PCR, in
- Figure 5 Gel mobility shift analysis of STAT DNA binding in vivo in response to leptin. An induction of STAT5 DNA binding activity to the ⁇ -casein promoter STAT5 consensus element. Nuclear extracts were prepared and incubated with 32 P end-labelled probe and fractionated on a 4% native PAGE gel. Induction observed in +/+ and ob/ob jejunal nuclear extracts in response to a leptin administration (5mg/kg) after 30 minutes.
- FIG. 6 Gel mobility shift analysis of STAT DNA binding in CACO-2 cells in response to leptin. An induction of STAT3 and STAT5 DNA binding activity in response to leptin (20-200nM, 15 minutes) is shown. A dose response relationship is observed in
- the complex is identified by preincubation with a anti-STAT3 and anti-STATl antibodies.
- STAT5 DNA binding to the ⁇ -casein probe is also observed in nuclear extracts of CACO-2 cells after leptin treatment.
- the major protein complex was identified by preincubation with anti-STAT5b specific antibody.
- Figure 7 Leptin induction of immediate-early gene transcription in mouse jejunum and in the human CACO-2 cells.
- Leptin administration reduces APO-AIV mRNA levels after high fat load.
- Leptin (5mg/kg) treatment results in a significant 2-fold reduction in APO-AIV mRNA levels in jejunum of ob/ob mice. Mice were fasted for 5 hours and given leptin intravenously 15 minutes before administration of fat load (0.75ml vegetable oil). 90 minutes later mice were sacrificed and the jejunum removed for RNA extraction.
- the methodology by which the CaCo-2 cell line was identified as a leptin responsive cell line is described below.
- General methodology for identification of leptin responsive cell lines is known and for example includes the following :-
- Microphysiometer This method detects small changes in pH resulting from biochemical changes in the cell. Ob-protein responsive cells upon stimulation may undergo biochemical changes that cause a small change in the extracellular acidification rate which can be detected by a silicon microphysiometer.
- the microphysiometer biosensor methodology has been reviewed by McConnell, Science, 1992, 257, 1906.
- Electrophoretic mobility shift assay Nuclear extracts from cells after treatment with ob-protein are mixed with radiolabeled oligonucleotides containing a promiscuous or specific STAT response element DNA sequence. Extracts from cells that respond to the ob-protein may cause a gel shift of the oligonucleotide for the STAT response element.
- JAK/ STAT antibodies may be used alongside antibodies for tyrosine phosphorylation to detect leptin activation in a leptin responsive cell line. Inhibition as well as stimulation of protein phosphorylation may occur. In particular, inhibition by the ob-protein of insulin stimulated phosphorylation of the insulin receptor and insulin receptor substrate- 1 has been shown in rat-1 fibroblasts over expressing insulin receptors (Kroder et. al 1996, Exp. Clin. Endocrinol. Diabetes, 104, suppl 2, p66)
- Displacement binding After incubation of cell lines with radiolabelled leptin, for example [l2 ⁇ ]_ ⁇ e p tmj me non-specific binding versus specific binding of leptin can studied by the addition of unlabelled leptin. A high specific to non-specific ratio binding suggests that the cell line may contain the leptin receptor.
- mRNA for a functional form preferably a functional long form, of the ob-receptor by Northern, RT-PCR or "slot blot" analysis.
- C-fos mRNA may be detected by Northern, RT-PCR or "slot blot" analysis.
- the response element, the reporter, and preferably the promoter are suitably incorporated into a vector capable of transfecting the ob-responsive cell line.
- Suitable vectors are commercially available vectors, such as pGL2-basic luciferase vector (Promega).
- a suitable configuration of the vector is the STAT DNA response element upstream of a promoter and a reporter gene.
- a more suitable configuration of the vector is the STAT DNA response element in multiple tandem repeats (2-10) upstream of a thymidine kinase promoter and a luciferase reporter gene
- Vectors are constructed containing a reporter gene for example firefly luciferase or chloramphenicol acetyltransferase enzyme linked to a minimal promoter for example the herpes simplex virus thymidine kinase or SV40 promoter.
- a reporter gene for example firefly luciferase or chloramphenicol acetyltransferase enzyme linked to a minimal promoter for example the herpes simplex virus thymidine kinase or SV40 promoter.
- the DNA fragments for the STAT response element are inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter.
- the response element, the reporter and the promoter are incorporated into the vector using conventional expression techniques, for example the DNA fragments for the response element may be inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter.
- STAT response element-luciferase enzyme reporter systems can be constructed as described by Lamb et al., Blood, 1994, 8, 2063 and Seidel et al., Proc. Nat. Acad. Sci. USA., 1995, 92, 3041.
- Leptin-responsive cells are transfected with the STAT response element-minimal promoter-luciferase reporter constructs using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection (12- 24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate ⁇ - galactosidase, activity.
- Potentiation or antagonist activity can be assayed by pre- or co- addition of an appropriate concentration of leptin to the compound under evaluation and measuring the potentiation or reduction in luciferase response relative to that of leptin alone.
- Standard methods exist for assaying luciferase enzyme activity for example Ow et al, Science, 1986, 234, 856 and de Wet et al., Mol. Cell Biol, 1987, 7, 725. as well as several commercial kits.
- Stable cell lines can be generated by transfecting an leptin-responsive cell line with the reporter construct and a selectable marker. Selectable markers are routinely used to generate stable cell lines as described in Recombinant DNA, 2nd edition, J.D. Watson et. al., 1992, page 216. These stably transfected cell lines can be used to generate high throughput assays for compounds that mimic, potentiate or block the physiological effects of the leptin.
- the invention also extends to a compound that mimics, potentiates or inhibits the physiological effect of the leptin, when identified by the method disclosed herein.
- the invention also extends to a kit of parts adapted for use in the method disclosed herein.
- the invention also extends to the use of native or engineered CACO-2 cells to detect compounds that mimic, potentiate or inhibit the physiological effects of leptin by measuring other responses that leptin elicits in such cells.
- the invention also extends to the use of native or engineered CACO-2 cells to measure the functional activity of preparations of leptin mimetics , potentiators or inhibitors.
- a compound which mimics the physiological effects of leptin' refers to a compound which is capable of acting in the absence of the leptin to either stimulate leptin receptor to provide substantially the same physiological effect as the ob protein or to activate a response down stream of this receptor (post-receptor).
- a compound that potentiates the physiological effect of leptin' refers to a compound which enhances the potency and/or maximal physiological effect of leptin.
- a compound that inhibits the physiological effect of the leptin' refers to a compound which reduces or substantially blocks the physiological effect of leptin.
- the cDNA encoding the functional form of the polypeptide can be transfected under the control of a constitutive promoter, (eg a viral pro mo tor) or a regulatable promoter to optimise the expression of the polypeptide for the identification of agonists or antagonists as necessary.
- a constitutive promoter eg a viral pro mo tor
- a regulatable promoter to optimise the expression of the polypeptide for the identification of agonists or antagonists as necessary.
- the response element and the reporter are expressed in a cell line, wherein a constitutive or regulatable promoter has been engineered into a position upstream of the chromosomally encoded gene for the leptin receptor by the method of homologous recombination.
- Such methods are reviewed by Waldman, Critical Reviews in Oncology/Hematology, 1992, 12, 49 and a particular example is given in the Riele et al, Proceedings of the National Academy of Sciences, 1992, 89, 5128.
- the CaCo-2 cells are transfected with a reporter plasmid containing a STAT response element, in multiple tandem copies upstream of a minimal promoter for example herpes simplex thymidine kinase and a luciferase gene reporter construct using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456).
- a minimal promoter for example herpes simplex thymidine kinase and a luciferase gene reporter construct
- the cells can be co-transfected with a reference plasmid expressing ⁇ -galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed.
- the lysates are assayed for luciferase, and if appropriate ⁇ -galactosidase, activity.
- Antagonist activity can be assayed by pre- or co- addition of an appropriate concentration of leptin to the compound under evaluation and measuring the reduction in luciferase response relative to that of leptin alone.
- Standard methods exist for assaying luciferase enzyme activity for example Ow et al., Science, 1986, 234, 856 and de Wet et al., 1987, 7, 725. as well as several commercial kits.
- the adipocyte hormone, leptin activates STAT3 in the hypothalamus mediating increased satiety and increased energy expenditure.
- leptin mediated activation of the STAT pathway in vivo has not been established in tissues other than hypothalamus.
- leptin receptor expression and in vivo signalling in discrete regions of the mouse gut associated with lipid handling.
- Expression of the functional isoform, OB- Rb is restricted to the jejunum.
- Intravenous injection of leptin rapidly induced nuclear STAT5 DNA binding activity in jejunum of +/+ and obese (ob/ob) mice, but had no effect in the diabetic (db/db) mouse that lacks the OB-Rb isoform.
- NIDDM non-insulin dependent diabetes
- OB-R Leptin-receptor
- RT-PCR reverse transcription polymerase chain reaction
- JAK janus kinase
- STAT signal transducers and activators of transcription
- CACO-2 Human colon epithelial cell line
- APO-AIV apolipoprotein AIV.
- EMEM Earles minimal essential medium.
- mice and cells-Six week old female wild-type and ob/ob mice of the Aston strain were bred in house and were kept on a 12h light: 12h dark cycle with routine access to water and standard laboratory chow (Beekay rat and mouse toxicology diet, Bantin and Kingman, Hull, UK).
- leptin 5mg/kg
- leptin recombinant leptin (Peprotech, Rockyville, USA) dissolved in lOmM Tris administered by tail vein injection or lOmM Tris vehicle to controls. After the indicated times, mice were sacrificed by cervical dislocation and tissues dissected, cleaned and washed in ice- cold saline.
- Tissues were taken fresh for extraction of nuclear proteins as described below or snap-frozen in liquid N 2 and stored at -80°C.
- Human Caucasian colon epithelial cells, CACO-2 European animal cell culture, Porton Down, UK
- EMEM Earles minimal essential medium
- NEAA non essential amino acids
- 2mM L-glutamine 10% foetal calf serum
- lOOu/ml penicillin lOO ⁇ g/ml streptomycin (all from Gibco/BRL, UK) at 37°C in humidified 5% CO 2 / air cabinet, for 3-4 days before experiments.
- Cells were pre-incubated for 24 hours in serum-free supplemented EMEM with 0.1% BSA.
- Cells were then incubated in basal EMEM with 0.1% BSA with or without leptin at given concentrations or the Tris control vehicle.
- RNA expression-Total RNA was isolated from tissues and cells using RNaid plus kit (BIO 101, Inc. USA) and treated immediately with DNase I (Gibco/BRL, UK). Approximately RNA (4 ⁇ g) was used to generate cDNA with first-strand cDNA beads (Pharmacia, Biotech) and oligo (dT) 12 . 18 (Invitrogen). The integrity and loading of the RNA was studied by detection scanning of ribosomal rRNA bands (28S and 18S) in agarose gels. Potential contamination from fat was studied using leptin specific primers (Table I) in an RT-PCR amplification.
- RT-PCR detection of the multiple OB-R transcript isoforms in the mouse gut as well as the OB-Rb transcript in the CACO-2 cells was performed using oligonucleotide primers listed in Table I. All PCR amplifications were 2 performed using AmpiiTaq (PerkinElmer) at 95°C, 45sec denaturation, 57°C, 45 sec annealing, 72°C, 45 sec extension (except that for the long OB-Rb isoform extension was for 1 minute) in a Progene thermal cycler (Techne/Cambridge).
- PCR products were then cloned directly into a pCR-TRAP cloning system (GeneHunter Corp., USA) and the identity of PCR products confirmed by sequencing using ThermoSequenase terminator cycle sequencing kit (Amersham Life Sciences, UK).
- cDNA samples from +/+ and ob/ob mice were serially diluted and PCR performed at a fixed number of cycles (37 for OB-R and 30 for ⁇ -actin), as described previously (18).
- tissues were homogenised in ice-cold RIPA buffer (IX PBS, 1% IGEPAL, 0.5% sodiumdeoxycholate) containing protease inhibitor cocktail (Boehringer Mannheim, Germany) and the protein lysates used for a protein assay (Sigma Diagnostics, UK) and standard western analysis.
- Approximately 20 ⁇ g protein was mixed with gel loading buffer (4% SDS, lOOmM Tris, pH 6.8, lOOmM ⁇ - mercaptoethanol) and resolved on 10% SDS-PAGE.
- gel loading buffer 4% SDS, lOOmM Tris, pH 6.8, lOOmM ⁇ - mercaptoethanol
- Proteins were transferred to PVDF (Millipore, UK) membranes by electrotransfer and immunoblots performed by blocking in 2% BSA, lOmM Tris pH 7.4, lOOmM NaCl, 0.1% Tween 20 and the OB-R was detected with M-18 or N-20 antibodies (Santa Cruz Biothechnology, Inc., USA), STAT proteins were detected with STAT5 (C-17) (Santa Cruz Bio hechnology, Inc., USA) and STATl,-2,-3, and -6 (Transduction Laboratories, USA) antibodies. Bands were visualised using an ECL kit according to instructions (Amersham, UK). Nuclear extracts-CACO-2 cells were immediately placed on ice after treatment and the medium removed.
- Cells were quickly washed with ice cold PBS and then PBS with 5mM NaF, lOmM NaMoO 4 and ImM activated NaVO 3 .
- Cells were lysed with a hypotonic buffer (400 ⁇ l/25cm 2 ) containing lOmM HEPES, pH 7.9, lOmM NaMoO 4 , ImM NaVO 3 , ImM EDTA, ImM EGTA, ImM NaF, 0.125 ⁇ M Okadaic Acid, ImM DTT, 2 ⁇ g.ml leupeptin, 2 ⁇ g/ml aprotinin, 50 ⁇ g/ml AEBSF and 0.2% IGEPAL CA-630 detergent (Sigma, UK) by cell scraping and gentle trituration.
- a hypotonic buffer 400 ⁇ l/25cm 2
- lOmM HEPES pH 7.9
- lOmM NaMoO 4 ImM NaVO 3
- ImM EDTA ImM EG
- the lysate was incubated on ice for 5 minutes and the nuclei pelleted by microcentrifugation for 20 seconds at 14000rpm. The supernatant was discarded and the nuclei gently resuspended in lOO ⁇ l high salt buffer (hypotonic buffer plus 200mM NaCl, 20% glycerol). Nuclear protein was extracted by rotating the tubes for 30 minutes at 4°C and the debris pelleted by microcentrifugation at 14000rpm for 20 minutes. Nuclear extracts were aliquoted then snap-frozen in liquid N 2 before gel-mobility shift assay (see below).
- Tissues were dissected, washed in ice-cold saline, minced and then homogenised in 1 :10 w/v hypotonic lysis buffer and nuclear extracts obtained essentially as described for CACO-2 cells.
- Gel mobility shift assaysS ⁇ l nuclear extract was used for DNA binding studies with lOOng/reaction 32 P ⁇ -ATP end-labelled probe in DNA binding buffer (Tris lOmM, pH 7.5, 150mM NaCl, ImM DTT with l ⁇ g/ml polydeoxy Inosine/Cytidine (Pharmacia, Sweden) to block non-specific binding.
- the binding reaction was incubated at room temperature for 20 minutes and then resolved on a 4% native PAGE gel.
- oligonucleotide probes were the mutated high affinity human Serum Inducible Element (m67 SIE), 5 '-cat ttc ccg taa ate at -3', from the c-fos promoter and a rat ⁇ -Casein promoter element sequence, 5'-gga ctt ctt gga art aag gga-3'.
- Complementary oligonucleotide strands were annealed in Tris lOmM, pH 8.0, ImM EDTA, 50mM NaCl to a final concentration of 200ng/ ⁇ l, by heating the mixture to 90°C for 10 minutes and then allowing it to cool slowly to room temperature. Probes were labelled with 3U/ ⁇ l T4 Polynucleotide Kinase (Amersham, USB, UK) at 37°C for one hour with l ⁇ l 3 P ⁇ -ATP (6000Ci/mmol Amersham, UK).
- OB-R mRNA isoforms were detected using RT-PCR in discrete sections of the gastrointestinal tract (see Fig. 1 A).
- the different short isoforms, OB-Ra, OB-Rc, OB- Rd and OB-Re are expressed throughout the gut.
- the functional long OB-Rb mRNA is found to be predominantly expressed in jejunum (Fig. 1A).
- RT-PCR amplification of cDNA samples from jejunum of +/+ and ob/ob mice resulted in negative detection, whilst PCR amplification of a common extracellular domain of the OB-R in the same samples was readily obtained (Fig. IB).
- Fig. 1 A Western blot analysis of 20 ⁇ g crude protein lysates using antibodies raised against the carboxy terminal sequence of the short isoform OB-Ra, a predominant isoform in many tissues (18), results in a band with a predicted size of approximately 120 kDa protein, that is predominantly expressed in the small intestine of both +/+ and ob/ob mice (Fig. 2A).
- mice Overnight fasted +/+ and ob/ob mice were administered 5mg/kg recombinant murine leptin by tail vein injection. 30 minutes after injection, mice were sacrificed and the jejunum removed for preparation of nuclear extracts.
- the m67-SIE mutated high affinity STAT consensus binding element from the c-fos promoter preferentially binds STAT1 and STAT3, but binds STAT5 with low affinity. This probe did not reveal an induction of STAT DNA binding activity in response to leptin treatment in vivo in the mouse gut (data not shown).
- the rat ⁇ -casein promoter STAT DNA binding consensus element was used as a selective probe for STAT5 activity in vivo.
- 5mg/kg leptin treatment induced a marked activation of DNA binding activity in both +/+ and ob/ob mice and was not observed in control animals treated with Tris only (Fig.5A).
- the same dose of leptin injected into the db/db mice, which lack the OB-Rb isoform caused no activation of STAT5 DNA binding in nuclear extracts of jejunum (Fig. 5 A).
- leptin treated CACO-2 cells exhibited an activation of DNA binding activity of STAT5 to the ⁇ -casein probe, and supershift studies identified STAT5b as the major factor in the complex (Fig 6).
- leptin induces nuclear STAT5 DNA binding activity in both mouse jejunum and CACO-2 cells, however different isoforms of STAT5 seem to form the protein-DNA complex in these two systems.
- Leptin administration also produced an induction of the immediate early gene c-fos in the jejunum of ob/ob mice after 30 minutes (Fig. 7A).
- Intravenous injection of 5mg/kg leptin resulted in a 5-fold increase in c-fos mRNA levels as detected by northern blot analysis.
- leptin treatment for 30 minutes caused a dramatic increase in expression of the immediate early genes, c-fos, c-jun, junB and junD in the serum-deprived CACO-2 cells as determined by quantitative PCR (Fig 7B). Since activation of STAT5 is usually not associated with c-fos induction, these results could indicate that other pathways are being activated in addition to the STAT5 pathway in vivo.
- leptin The adipocyte hormone, leptin, signals to the hypothalamus to inhibit food intake and increase energy expenditure (1).
- Leptin has also been reported to play a role in peripheral tissue biology (8, 20, 23, 24). Leptin treatment of +/+ and ob/ob mice cause a reduction in body weight and fat mass in excess of that resulting from inhibition of food intake only (25). This would suggest that leptin can affect fat accumulation, metabolism and energy homeostasis that is in part independent of the regulation of food intake.
- leptin caused activation of the STATS signalling pathway in jejunum after 30 minutes in +/+ and ob/ob mice, but not in db/db mice which lack OB-Rb.
- Leptin also caused a reduction in the APO-AIV mRNA 90 minutes after administration of high fat load.
- the immediate and direct effect of leptin on jejunal lipid handling could represent a front-line mechanism against fat accumulation.
- the short OB-R isoforms are widely expressed in tissues whilst the long OB-Rb isoform is more restricted in tissue distribution (7).
- OB-Rb is relatively well expressed in hypothalamus, particularly in regions associated with the regulation of body weight homeostasis (26).
- OB-Rb peripheral tissues such as pancreatic islets, lymph nodes and hematopoietic stem cells (7,8,24).
- the short receptor isoforms which predominate in most tissues, are unable to mediate such a response to leptin, and no biological function has been assigned to these isoforms to date.
- the shorter OB-R isoforms can modify the activity of OB-Rb during homodimerization and subsequent aggregation of the cytosolic domain (7).
- This effect of the shorter isoforms seem weak, however, according to the recent data of White et al. (27) who demonstrate that the signalling capacity of OB-Rb is quite resistant to repression by the shorter receptor isoforms.
- the multiple short isoforms are expressed throughout the gastrointestinal tract whilst the functional OB-Rb is predominantly expressed in the jejunum and more weakly in ileum, the two major sites that are involved in lipid handling.
- STAT5 activation and immediate-early gene induction in response to leptin in the human model of small intestinal epithelium, the CACO-2 cell may be interpreted as corroboration of a direct effect of leptin on enterocytes. That the associated activation of STAT3 and STAT5 in this cell line appears broader than the primary gut tissue is also a recognised phenomenon of in vitro systems (7).
- the requirement for depriving cells of serum before and during leptin treatment and the use of high concentrations of leptin for the demonstrated activation of the STAT DNA binding in CACO-2 cells has been observed previously in other cell-lines (29).
- STAT5 in mediating the effect of leptin on body weight homeostasis is further supported by in vitro evidence from the obese (fa/fa) Zucker rat, which contain a missense mutation (Gln->Pro) in the extracellular domain of the OB-R (30).
- OB-R(fa) mediates a leptin-independent (constitutive) activation of STAT1 and STAT3, whilst the activation of STAT5 is completely abolished (31).
- the small intestine forms the primary interface between ingested nutrient and the carefully regulated internal environment of an organism.
- endogenous intestinal triglyceride production is increased (32), contributing to elevated plasma triglyceride levels.
- Our results show for the first time that leptin can cause a rapid activation of STAT5 in jejunum which is associated with a reduction of the APO-AIV transcript levels 90 minutes after ingestion of a fatty meal. This suggests that leptin may play a physiological role in lipid handling at this site in vivo.
- the APO-AIV system serves as a conduit for transport of triglycerides as chylomicrons in the circulation and their transfer to acceptor membranes in various tissues.
- APO-AIV APO-AIV
- APO-AIV reducing APO-AIV could function as a buffer system to reduce the chylomicron triglyceride levels. It is also possible that leptin may serve as a tonic inhibitory mechanism on the APO-AIV system to reduce the levels of secreted triglycerides.
- leptin can induce enzymes of fatty acid oxidation (35) and thus promote a switch in fuel metabolism to ⁇ -oxidation of fatty acids (36).
- leptin can induce enzymes of fatty acid oxidation (35) and thus promote a switch in fuel metabolism to ⁇ -oxidation of fatty acids (36).
- leptin can induce enzymes of fatty acid oxidation (35) and thus promote a switch in fuel metabolism to ⁇ -oxidation of fatty acids (36).
- This may represent a negative feedback signal from fat stores to the primary site of lipid handling, an adipo-enteric loop that contributes to the anti-obesity effects of leptin.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14007599A IL140075A0 (en) | 1998-06-30 | 1999-06-28 | Method for detection of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
EP99932753A EP1092048A2 (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
KR1020007015081A KR20010053331A (en) | 1998-06-30 | 1999-06-28 | Method for Detecting of a Compound that Mimics, Potentiates or Inhibits the Physiological Effect of Leptin |
AU49024/99A AU4902499A (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
HU0102809A HUP0102809A2 (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
CA002335557A CA2335557A1 (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
PL99345382A PL345382A1 (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
BR9911643-0A BR9911643A (en) | 1998-06-30 | 1999-06-28 | Process for detecting a compound that mimics, enhances or inhibits the physiological effect of leptin |
NO20006541A NO20006541L (en) | 1998-06-30 | 2000-12-21 | Method for detecting a compound that mimics, potentiates or inhibits the physiological effect of leptin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9814199.7A GB9814199D0 (en) | 1998-06-30 | 1998-06-30 | Novel method |
GB9814199.7 | 1998-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000000639A2 true WO2000000639A2 (en) | 2000-01-06 |
WO2000000639A3 WO2000000639A3 (en) | 2000-08-17 |
Family
ID=10834721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/004501 WO2000000639A2 (en) | 1998-06-30 | 1999-06-28 | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1092048A2 (en) |
KR (1) | KR20010053331A (en) |
CN (1) | CN1316015A (en) |
AR (1) | AR020100A1 (en) |
AU (1) | AU4902499A (en) |
BR (1) | BR9911643A (en) |
CA (1) | CA2335557A1 (en) |
GB (1) | GB9814199D0 (en) |
HU (1) | HUP0102809A2 (en) |
IL (1) | IL140075A0 (en) |
NO (1) | NO20006541L (en) |
PL (1) | PL345382A1 (en) |
TR (1) | TR200003887T2 (en) |
WO (1) | WO2000000639A2 (en) |
ZA (1) | ZA200007689B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106636000A (en) * | 2016-12-23 | 2017-05-10 | 广东圣赛生物科技有限公司 | hESCs-TK cell line and building method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038586A1 (en) * | 1995-05-30 | 1996-12-05 | Smithkline Beecham Plc | Method for the detection of compounds that modulate the effects of the obese protein |
WO1997035005A2 (en) * | 1996-03-20 | 1997-09-25 | Isis Innovation Limited | Cftr gene regulator |
WO1998020158A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Plc | Method for the detection of compounds that modulate the effects of the obese (ob) protein |
-
1998
- 1998-06-30 GB GBGB9814199.7A patent/GB9814199D0/en not_active Ceased
-
1999
- 1999-06-28 IL IL14007599A patent/IL140075A0/en unknown
- 1999-06-28 EP EP99932753A patent/EP1092048A2/en not_active Withdrawn
- 1999-06-28 BR BR9911643-0A patent/BR9911643A/en not_active Application Discontinuation
- 1999-06-28 CA CA002335557A patent/CA2335557A1/en not_active Abandoned
- 1999-06-28 TR TR2000/03887T patent/TR200003887T2/en unknown
- 1999-06-28 PL PL99345382A patent/PL345382A1/en not_active Application Discontinuation
- 1999-06-28 CN CN99808215A patent/CN1316015A/en active Pending
- 1999-06-28 HU HU0102809A patent/HUP0102809A2/en unknown
- 1999-06-28 KR KR1020007015081A patent/KR20010053331A/en not_active Application Discontinuation
- 1999-06-28 WO PCT/EP1999/004501 patent/WO2000000639A2/en not_active Application Discontinuation
- 1999-06-28 AU AU49024/99A patent/AU4902499A/en not_active Abandoned
- 1999-06-29 AR ARP990103134A patent/AR020100A1/en unknown
-
2000
- 2000-12-20 ZA ZA200007689A patent/ZA200007689B/en unknown
- 2000-12-21 NO NO20006541A patent/NO20006541L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038586A1 (en) * | 1995-05-30 | 1996-12-05 | Smithkline Beecham Plc | Method for the detection of compounds that modulate the effects of the obese protein |
WO1997035005A2 (en) * | 1996-03-20 | 1997-09-25 | Isis Innovation Limited | Cftr gene regulator |
WO1998020158A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Plc | Method for the detection of compounds that modulate the effects of the obese (ob) protein |
Non-Patent Citations (3)
Title |
---|
GHILARDI N ET AL: "DEFECTIVE STAT SIGNALING BY THE LEPTIN RECEPTOR IN DIABETIC MICE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, 1 June 1996 (1996-06-01), pages 6231-6235, XP002030820 ISSN: 0027-8424 cited in the application * |
MORTON N M ET AL.: "Leptin signalling in pancreatic islets and clonal insulin-secreting cells" JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 22, 1999, pages 173-184, XP000905489 * |
SEIDEL H M ET AL: "SPACING OF PALINDROMIC HALF SITES AS A DETERMINANT OF SELECTIVE STAT (SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCIPTION) DNA BINDING AND TRANSCIPTIONAL ACTIVITY" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 March 1995 (1995-03-01), pages 3041-3045, XP002009232 ISSN: 0027-8424 cited in the application * |
Also Published As
Publication number | Publication date |
---|---|
IL140075A0 (en) | 2002-02-10 |
BR9911643A (en) | 2001-03-20 |
NO20006541D0 (en) | 2000-12-21 |
NO20006541L (en) | 2000-12-21 |
KR20010053331A (en) | 2001-06-25 |
CN1316015A (en) | 2001-10-03 |
WO2000000639A3 (en) | 2000-08-17 |
HUP0102809A2 (en) | 2001-12-28 |
ZA200007689B (en) | 2001-12-12 |
EP1092048A2 (en) | 2001-04-18 |
AR020100A1 (en) | 2002-04-10 |
AU4902499A (en) | 2000-01-17 |
GB9814199D0 (en) | 1998-08-26 |
CA2335557A1 (en) | 2000-01-06 |
PL345382A1 (en) | 2001-12-17 |
TR200003887T2 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morton et al. | Leptin action in intestinal cells | |
Sinha et al. | Clinical aspects of leptin | |
Laud et al. | Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line | |
Laubner et al. | Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signaling 3 in pancreatic β-cells | |
Rosenblum et al. | Functional STAT 1 and 3 signaling by the leptin receptor (OB-R); reduced expression of the rat fatty leptin receptor in transfected cells | |
Hansen et al. | Characterization of the inhibitory effect of growth hormone on primary preadipocyte differentiation | |
Islam et al. | Rat insulinoma-derived pancreatic β-cells express a functional leptin receptor that mediates a proliferative response | |
Luoh et al. | Cloning and characterization of a human leptin receptor using a biologically active leptin immunoadhesin | |
Bendinelli et al. | Leptin activates Stat3, Stat1 and AP-1 in mouse adipose tissue | |
De Vos et al. | Glucocorticoids induce the expression of the leptin gene through a non‐classical mechanism of transcriptional activation | |
EP1101112B1 (en) | Leptin-mediated gene-induction | |
Futawaka et al. | Growth hormone regulates the expression of UCP2 in myocytes | |
Finidori | Regulators of growth hormone signaling | |
AU715215B2 (en) | Method for the detection of compounds that modulate the effects of the obese protein | |
Rosenblum et al. | A rapid, quantitative functional assay for measuring leptin | |
EP1092048A2 (en) | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin | |
MXPA01000149A (en) | Method for detecting of a compound that mimics, potentiates or inhibits the physiological effect of leptin | |
Kita et al. | Vanadate enhances leptin-induced activation of JAK/STAT pathway in CHO cells | |
CZ20004897A3 (en) | Method for detecting a compound that mimics, potentiates or inhibits the physiological effect of leptin | |
Sharma et al. | Analysis of the role of E2A-encoded proteins in insulin gene transcription | |
Magenheim et al. | Negative autoregulation of HNF-4α gene expression by HNF-4α1 | |
BILLESTRUP et al. | Molecular mechanism of growth hormone signalling | |
JP2001503982A (en) | Method for detecting a compound that modulates the effect of obesity (OB) protein | |
EP1121457B1 (en) | Use of socs-2 or cis to screen for compounds enhancing growth hormone effect | |
WO1999004264A1 (en) | Method for identifying modifiers of the leptin: leptin receptor interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99808215.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140075 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49024/99 Country of ref document: AU Ref document number: 1999932753 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/07689 Country of ref document: ZA Ref document number: 200007689 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2000/00766/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/03887 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-4897 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2000 557392 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007015081 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/000149 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1999932753 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-4897 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007015081 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2335557 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-4897 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999932753 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007015081 Country of ref document: KR |